T-knife Therapeutics

T-knife is a biopharmaceutical company founded in 2018 and headquartered in the United States. The company's slogan, "T-knife uses a mouse platform to create human TCRs for cancer treatment without modification," encapsulates its unique approach to developing novel therapeutics for fighting cancer. Leveraging its proprietary HuTCR mouse platform, T-knife aims to generate fully human, tumor-specific TCRs naturally selected in vivo for optimal affinity and high specificity. The company is focused on developing T cell receptor (TCR) engineered T cell therapies (TCR-Ts) to address high unmet medical needs in cancer treatment. Its portfolio includes TCR-T product candidates targeting various antigens, including cancer testis antigens, oncoviral antigens, and commonly shared tumor-driving neoantigens. The innovative technology was developed in collaboration with the Max Delbruck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, and the recent Series B funding round raised a substantial $110.00M. Investors in this round included Casdin Capital, RA Capital Management, Versant Ventures, Qatar Investment Authority, 60 Degree Capital, Andera Partner, CaaS Capital Management, Fidelity, and EQT Life Sciences.